<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05590000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P04626</UniProt_ID>
  <Seq_Length>1255</Seq_Length>
  <Molecule_Weight>137910</Molecule_Weight>
  <KEGG_ID>hsa:2064</KEGG_ID>
  <Orthology_ID>K05083</Orthology_ID>
  <EBI_ID>EBI-641062</EBI_ID>
  <Function_Summary>Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF00757:Furin-like@@PF07714:Pkinase_Tyr@@PF01030:Recep_L_domain</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>1</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>7</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Proto-oncogene c-ErbB-2</Alias>
      <Alias>Proto-oncogene Neu</Alias>
      <Alias>p185erbB2</Alias>
      <Alias>Metastatic lymph node gene 19 protein</Alias>
      <Alias>Tyrosine kinase-type cell surface receptor HER2</Alias>
      <Alias>MLN 19</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein or proteins.</Detail>
      <Keyword>Identical protein binding</Keyword>
      <Ontology_ID>GO:0042802</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an epidermal growth factor to initiate a change in cell activity.</Detail>
      <Keyword>Epidermal growth factor receptor activity</Keyword>
      <Ontology_ID>GO:0005006</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein C-terminus, the end of any peptide chain at which the 1-carboxy function of a constituent amino acid is not attached in peptide linkage to another amino-acid residue.</Detail>
      <Keyword>Protein C-terminus binding</Keyword>
      <Ontology_ID>GO:0008022</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nonidentical protein to form a heterodimer.</Detail>
      <Keyword>Protein heterodimerization activity</Keyword>
      <Ontology_ID>GO:0046982</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protein phosphatase.</Detail>
      <Keyword>Protein phosphatase binding</Keyword>
      <Ontology_ID>GO:0019903</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Protein that positively regulates either the transcription of one or more genes, or the translation of mRNA.</Detail>
      <Keyword>Activator</Keyword>
      <Ontology_ID>KW-0010</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the protein-tyrosine kinase receptor ErbB-3/HER3.</Detail>
      <Keyword>ErbB-3 class receptor binding</Keyword>
      <Ontology_ID>GO:0043125</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + receptor signalling protein tyrosine = ADP + receptor signalling protein phosphate.</Detail>
      <Keyword>Receptor signaling protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004716</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with RNA polymerase I core enzyme, a multisubunit eukaryotic nuclear RNA polymerase typically composed of seventeen subunits.</Detail>
      <Keyword>RNA polymerase I core binding</Keyword>
      <Ontology_ID>GO:0001042</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>655</Position>
      <Original>Ile</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>1170</Position>
      <Original>Pro</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>857</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>768</Position>
      <Original>Leu</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>654</Position>
      <Original>Ile</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>755</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>914</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>776</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1216</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>452</Position>
      <Original>Trp</Original>
      <Variation>Cys</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of epithelial cell proliferation.</Detail>
      <Keyword>Positive regulation of epithelial cell proliferation</Keyword>
      <Ontology_ID>GO:0050679</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of events that restore integrity to a damaged tissue, following an injury.</Detail>
      <Keyword>Wound healing</Keyword>
      <Ontology_ID>GO:0042060</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The multiplication or reproduction of cells, resulting in the expansion of a cell population.</Detail>
      <Keyword>Cell proliferation</Keyword>
      <Ontology_ID>GO:0008283</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of angiogenesis.</Detail>
      <Keyword>Regulation of angiogenesis</Keyword>
      <Ontology_ID>GO:0045765</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.</Detail>
      <Keyword>Regulation of ERK1 and ERK2 cascade</Keyword>
      <Ontology_ID>GO:0070372</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase III promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase III promoter</Keyword>
      <Ontology_ID>GO:0045945</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase I promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase I promoter</Keyword>
      <Ontology_ID>GO:0045943</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA.</Detail>
      <Keyword>Positive regulation of translation</Keyword>
      <Ontology_ID>GO:0045727</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of any cellular process that depends upon or alters the microtubule cytoskeleton.</Detail>
      <Keyword>Regulation of microtubule-based process</Keyword>
      <Ontology_ID>GO:0032886</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell adhesion.</Detail>
      <Keyword>Positive regulation of cell adhesion</Keyword>
      <Ontology_ID>GO:0045785</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.</Detail>
      <Keyword>Positive regulation of protein phosphorylation</Keyword>
      <Ontology_ID>GO:0001934</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the heart over time, from its formation to the mature structure. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.</Detail>
      <Keyword>Heart development</Keyword>
      <Ontology_ID>GO:0007507</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of RNA on a template of DNA.</Detail>
      <Keyword>Transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0006351</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the activity of a GTPase of the Rho family.</Detail>
      <Keyword>Positive regulation of Rho GTPase activity</Keyword>
      <Ontology_ID>GO:0032321</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.</Detail>
      <Keyword>Protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0046777</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of reactions, mediated by the intracellular phosphatidylinositol 3-kinase (PI3K). PI3K cascades lie downstream of many cell surface receptor linked signaling pathways and regulate numerous cellular functions.</Detail>
      <Keyword>Phosphatidylinositol 3-kinase cascade</Keyword>
      <Ontology_ID>GO:0014065</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of cell growth.</Detail>
      <Keyword>Positive regulation of cell growth</Keyword>
      <Ontology_ID>GO:0030307</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of MAP kinase activity.</Detail>
      <Keyword>Positive regulation of MAP kinase activity</Keyword>
      <Ontology_ID>GO:0043406</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>1248</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>735</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1054</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1196</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>1139</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV</Protein_Seq>
    <DNA_Seq>GTTCCCGGATTTTTGTGGGCGCCTGCCCCGCCCCTCGTCCCCCTGCTGTGTCCATATATCGAGGCGATAGGGTTAAGGGAAGGCGGACGCCTGATGGGTTAATGAGCAAACTGAAGTGTTTTCCATGATCTTTTTTGAGTCGCAATTGAAGTACCACCTCCCGAGGGTGATTGCTTCCCCATGCGGGGTAGAACCTTTGCTGTCCTGTTCACCACTCTACCTCCAGCACAGAATTTGGCTTATGCCTACTCAATGTGAAGATGATGAGGATGAAAACCTTTGTGATGATCCACTTCCACTTAATGAATGGTGGCAAAGCAAAGCTATATTCAAGACCACATGCAAAGCTACTCCCTGAGCAAAGAGTCACAGATAAAACGGGGGCACCAGTAGAATGGCCAGGACAAACGCAGTGCAGCACAGAGACTCAGACCCTGGCAGCCATGCCTGCGCAGGCAGTGATGAGAGTGACATGTACTGTTGTGGACATGCACAAAAGTGAGTGTGCACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCCGTGCTAGACAATGGAGACCCGCTGAACAATACCACCCCTGTCACAGGGGCCTCCCCAGGAGGCCTGCGGGAGCTGCAGCTTCGAAGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCCAGCTCTGCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCTCTCACACTGATAGACACCAACCGCTCTCGGGCCTGCCACCCCTGTTCTCCGATGTGTAAGGGCTCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTCAGAGCCTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAGGGGCCACTGCCCACTGACTGCTGCCATGAGCAGTGTGCTGCCGGCTGCACGGGCCCCAAGCACTCTGACTGCCTGGCCTGCCTCCACTTCAACCACAGTGGCATCTGTGAGCTGCACTGCCCAGCCCTGGTCACCTACAACACAGACACGTTTGAGTCCATGCCCAATCCCGAGGGCCGGTATACATTCGGCGCCAGCTGTGTGACTGCCTGTCCCTACAACTACCTTTCTACGGACGTGGGATCCTGCACCCTCGTCTGCCCCCTGCACAACCAAGAGGTGACAGCAGAGGATGGAACACAGCGGTGTGAGAAGTGCAGCAAGCCCTGTGCCCGAGTGTGCTATGGTCTGGGCATGGAGCACTTGCGAGAGGTGAGGGCAGTTACCAGTGCCAATATCCAGGAGTTTGCTGGCTGCAAGAAGATCTTTGGGAGCCTGGCATTTCTGCCGGAGAGCTTTGATGGGGACCCAGCCTCCAACACTGCCCCGCTCCAGCCAGAGCAGCTCCAAGTGTTTGAGACTCTGGAAGAGATCACAGGTTACCTATACATCTCAGCATGGCCGGACAGCCTGCCTGACCTCAGCGTCTTCCAGAACCTGCAAGTAATCCGGGGACGAATTCTGCACAATGGCGCCTACTCGCTGACCCTGCAAGGGCTGGGCATCAGCTGGCTGGGGCTGCGCTCACTGAGGGAACTGGGCAGTGGACTGGCCCTCATCCACCATAACACCCACCTCTGCTTCGTGCACACGGTGCCCTGGGACCAGCTCTTTCGGAACCCGCACCAAGCTCTGCTCCACACTGCCAACCGGCCAGAGGACGAGTGTGTGGGCGAGGGCCTGGCCTGCCACCAGCTGTGCGCCCGAGGGCACTGCTGGGGTCCAGGGCCCACCCAGTGTGTCAACTGCAGCCAGTTCCTTCGGGGCCAGGAGTGCGTGGAGGAATGCCGAGTACTGCAGGGGCTCCCCAGGGAGTATGTGAATGCCAGGCACTGTTTGCCGTGCCACCCTGAGTGTCAGCCCCAGAATGGCTCAGTGACCTGTTTTGGACCGGAGGCTGACCAGTGTGTGGCCTGTGCCCACTATAAGGACCCTCCCTTCTGCGTGGCCCGCTGCCCCAGCGGTGTGAAACCTGACCTCTCCTACATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCGCATGCCAGCCTTGCCCCATCAACTGCACCCACTCCTGTGTGGACCTGGATGACAAGGGCTGCCCCGCCGAGCAGAGAGCCAGCCCTCTGACGTCCATCATCTCTGCGGTGGTTGGCATTCTGCTGGTCGTGGTCTTGGGGGTGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAGAAGATCCGGAAGTACACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTGACACCTAGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTGAGGAAGGTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGGATCCCTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAACACATCCCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACGTGATGGCTGGTGTGGGCTCCCCATATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGCTGGTGACACAGCTTATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCGGACGCCTGGGCTCCCAGGACCTGCTGAACTGGTGTATGCAGATTGCCAAGGGGATGAGCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCTGGTCAAGAGTCCCAACCATGTCAAAATTACAGACTTCGGGCTGGCTCGGCTGCTGGACATTGACGAGACAGAGTACCATGCAGATGGGGGCAAGGTGCCCATCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTTCACCCACCAGAGTGATGTGTGGAGTTATGGTGTGACTGTGTGGGAGCTGATGACTTTTGGGGCCAAACCTTACGATGGGATCCCAGCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGGCTGCCCCAGCCCCCCATCTGCACCATTGATGTCTACATGATCATGGTCAAATGTTGGATGATTGACTCTGAATGTCGGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGGGACCCCCAGCGCTTTGTGGTCATCCAGAATGAGGACTTGGGCCCAGCCAGTCCCTTGGACAGCACCTTCTACCGCTCACTGCTGGAGGACGATGACATGGGGGACCTGGTGGATGCTGAGGAGTATCTGGTACCCCAGCAGGGCTTCTTCTGTCCAGACCCTGCCCCGGGCGCTGGGGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGTGGGGACCTGACACTAGGGCTGGAGCCCTCTGAAGAGGAGGCCCCCAGGTCTCCACTGGCACCCTCCGAAGGGGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGCTGCAAAGCCTCCCCACACATGACCCCAGCCCTCTACAGCGGTACAGTGAGGACCCCACAGTACCCCTGCCCTCTGAGACTGATGGCTACGTTGCCCCCCTGACCTGCAGCCCCCAGCCTGAATATGTGAACCAGCCAGATGTTCGGCCCCAGCCCCCTTCGCCCCGAGAGGGCCCTCTGCCTGCTGCCCGACCTGCTGGTGCCACTCTGGAAAGGCCCAAGACTCTCTCCCCAGGGAAGAATGGGGTCGTCAAAGACGTTTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTGACACCCCAGGGAGGAGCTGCCCCTCAGCCCCACCCTCCTCCTGCCTTCAGCCCAGCCTTCGACAACCTCTATTACTGGGACCAGGACCCACCAGAGCGGGGGGCTCCACCCAGCACCTTCAAAGGGACACCTACGGCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCAGTGTGAACCAGAAGGCCAAGTCCGCAGAAGCCCTGATGTGTCCTCAGGGAGCAGGGAAGGCCTGACTTCTGCTGGCATCAAGAGGTGGGAGGGCCCTCCGACCACTTCCAGGGGAACCTGCCATGCCAGGAACCTGTCCTAAGGAACCTTCCTTCCTGCTTGAGTTCCCAGATGGCTGGAAGGGGTCCAGCCTCGTTGGAAGAGGAACAGCACTGGGGAGTCTTTGTGGATTCTGAGGCCCTGCCCAATGAGACTCTAGGGTCCAGTGGATGCCACAGCCCAGCTTGGCCCTTTCCTTCCAGATCCTGGGTACTGAAAGCCTTAGGGAAGCTGGCCTGAGAGGGGAAGCGGCCCTAAGGGAGTGTCTAAGAACAAAAGCGACCCATTCAGAGACTGTCCCTGAAACCTAGTACTGCCCCCCATGAGGAAGGAACAGCAATGGTGTCAGTATCCAGGCTTTGTACAGAGTGCTTTTCTGTTTAGTTTTTACTTTTTTTGTTTTGTTTTTTTAAAGATGAAATAAAGACCCAGGGGGAGAATGGGTGTTGTATGGGGAGGCAAGTGTGGGGGGTCCTTCTCCACACCCACTTTGTCCATTTGCAAATATATTTTGGAAAACAGCTA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Breast tumors</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney tumors</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Esophagus tumors</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Mouth tumors</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Small bowel tumors</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Receptor complex</CellLocal>
      <Ontology_ID>GO:0043235</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to membrane</CellLocal>
      <Ontology_ID>GO:0016021</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endosome membrane</CellLocal>
      <Ontology_ID>GO:0010008</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Perinuclear region of cytoplasm</CellLocal>
      <Ontology_ID>GO:0048471</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>ERBB2</Gene_Name>
    <Gene_Alias>HER2; MLN19; NEU; NGL</Gene_Alias>
    <Gene_ID>2064</Gene_ID>
    <Genbank_ACCN>NM_001005862</Genbank_ACCN>
    <Protein_ACCN>NP_001005862</Protein_ACCN>
    <HGNC_ID>3430</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2064</Gene_URL>
    <UCSC_ID>uc010cwa.3</UCSC_ID>
    <EMBL_ID>ENSG00000141736</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P23467</Uniprot_ID>
      <Gene_Name>PTPRB</Gene_Name>
      <EBI_ID>EBI-1265766</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-1265766</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O00750</Uniprot_ID>
      <Gene_Name>PIK3C2B</Gene_Name>
      <EBI_ID>EBI-641107</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-641107</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q12913</Uniprot_ID>
      <Gene_Name>PTPRJ</Gene_Name>
      <EBI_ID>EBI-2264500</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-2264500</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q05209</Uniprot_ID>
      <Gene_Name>PTPN12</Gene_Name>
      <EBI_ID>EBI-2266035</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-2266035</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O14980</Uniprot_ID>
      <Gene_Name>XPO1</Gene_Name>
      <EBI_ID>EBI-355867</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-355867</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14974</Uniprot_ID>
      <Gene_Name>KPNB1</Gene_Name>
      <EBI_ID>EBI-286758</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-286758</PPI_EBI_URL>
      <Experiment_Number>14</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15075</Uniprot_ID>
      <Gene_Name>EEA1</Gene_Name>
      <EBI_ID>EBI-298113</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-298113</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15262</Uniprot_ID>
      <Gene_Name>PTPRK</Gene_Name>
      <EBI_ID>EBI-474052</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-474052</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P46940</Uniprot_ID>
      <Gene_Name>IQGAP1</Gene_Name>
      <EBI_ID>EBI-297509</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-297509</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P12931</Uniprot_ID>
      <Gene_Name>SRC</Gene_Name>
      <EBI_ID>EBI-621482</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-621482</PPI_EBI_URL>
      <Experiment_Number>10</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P04626</Uniprot_ID>
      <Gene_Name>ERBB2</Gene_Name>
      <EBI_ID>EBI-641062</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-641062</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P60709</Uniprot_ID>
      <Gene_Name>ACTB</Gene_Name>
      <EBI_ID>EBI-353944</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-353944</PPI_EBI_URL>
      <Experiment_Number>10</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q16827</Uniprot_ID>
      <Gene_Name>PTPRO</Gene_Name>
      <EBI_ID>EBI-723739</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-723739</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P98172</Uniprot_ID>
      <Gene_Name>EFNB1</Gene_Name>
      <EBI_ID>EBI-538287</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-538287</PPI_EBI_URL>
      <Experiment_Number>11</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O95602</Uniprot_ID>
      <Gene_Name>POLR1A</Gene_Name>
      <EBI_ID>EBI-359472</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-359472</PPI_EBI_URL>
      <Experiment_Number>16</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P08575</Uniprot_ID>
      <Gene_Name>PTPRC</Gene_Name>
      <EBI_ID>EBI-1341</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-1341</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15303</Uniprot_ID>
      <Gene_Name>ERBB4</Gene_Name>
      <EBI_ID>EBI-80371</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-80371</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q02297-7</Uniprot_ID>
      <Gene_Name>NRG1</Gene_Name>
      <EBI_ID>EBI-2460927</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-2460927</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P21860</Uniprot_ID>
      <Gene_Name>ERBB3</Gene_Name>
      <EBI_ID>EBI-720706</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-720706</PPI_EBI_URL>
      <Experiment_Number>15</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P00533</Uniprot_ID>
      <Gene_Name>EGFR</Gene_Name>
      <EBI_ID>EBI-297353</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-297353</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P49792</Uniprot_ID>
      <Gene_Name>RANBP2</Gene_Name>
      <EBI_ID>EBI-973138</EBI_ID>
      <PPI_EBI_URL>EBI-641062,EBI-973138</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Breast Fibroadenoma</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_fibroadenoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glioblastoma</Disease_Name>
      <Disease_Detail>Glioblastoma</Disease_Detail>
      <Disease_DB>GLB002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glioblastoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastric Cancer, Somatic</Disease_Name>
      <Disease_Detail>Gastric Cancer</Disease_Detail>
      <Disease_DB>GST060</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastric_cancer_somatic?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenocarcinoma of Lung, Somatic</Disease_Name>
      <Disease_Detail>Adenocarcinoma</Disease_Detail>
      <Disease_DB>ADN033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenocarcinoma_of_lung_somatic?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transitional Cell Carcinoma</Disease_Name>
      <Disease_Detail>Transitional Cell Carcinoma</Disease_Detail>
      <Disease_DB>TRN018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transitional_cell_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Nonseminomatous Germ Cell Tumor</Disease_Name>
      <Disease_Detail>Nonseminomatous Germ Cell Tumor</Disease_Detail>
      <Disease_DB>NNS011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/nonseminomatous_germ_cell_tumor?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Microglandular Adenosis</Disease_Name>
      <Disease_Detail>Microglandular Adenosis</Disease_Detail>
      <Disease_DB>MCR019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/microglandular_adenosis?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ewing's Family of Tumors</Disease_Name>
      <Disease_Detail>Ewing's Family of Tumors</Disease_Detail>
      <Disease_DB>EWN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ewings_family_of_tumors?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Pulmonary Airway Malformation</Disease_Name>
      <Disease_Detail>Congenital Pulmonary Airway Malformation</Disease_Detail>
      <Disease_DB>CNG390</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_pulmonary_airway_malformation?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bile Duct Adenoma</Disease_Name>
      <Disease_Detail>Bile Duct Carcinoma</Disease_Detail>
      <Disease_DB>BLD033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bile_duct_adenoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Charcot-Marie-Tooth Disease Type 1a</Disease_Name>
      <Disease_Detail>Charcot-Marie-Tooth Disease</Disease_Detail>
      <Disease_DB>CHR129</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/charcot_marie_tooth_disease_type_1a?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ductal Carcinoma in Situ</Disease_Name>
      <Disease_Detail>Ductal Carcinoma in Situ</Disease_Detail>
      <Disease_DB>DCT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ductal_carcinoma_in_situ?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sweat Gland Carcinoma</Disease_Name>
      <Disease_Detail>Sweat Gland Carcinoma</Disease_Detail>
      <Disease_DB>SWT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sweat_gland_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenocarcinoma, Ovarian, Somatic</Disease_Name>
      <Disease_Detail>Adenocarcinoma</Disease_Detail>
      <Disease_DB>ADN034</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenocarcinoma_ovarian_somatic?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Placental Site Trophoblastic Tumor</Disease_Name>
      <Disease_Detail>Placental Site Trophoblastic Tumor</Disease_Detail>
      <Disease_DB>PLC003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/placental_site_trophoblastic_tumor?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenocarcinoma</Disease_Name>
      <Disease_Detail>Adenocarcinoma</Disease_Detail>
      <Disease_DB>ADN016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenocarcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glioblastoma, Somatic</Disease_Name>
      <Disease_Detail>Glioblastoma</Disease_Detail>
      <Disease_DB>GLB008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glioblastoma_somatic?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cholangiocarcinoma</Disease_Name>
      <Disease_Detail>Cholangiocarcinoma</Disease_Detail>
      <Disease_DB>CHL065</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cholangiocarcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Medulloblastoma</Disease_Name>
      <Disease_Detail>Medulloblastoma</Disease_Detail>
      <Disease_DB>MDL005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/medulloblastoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neuroblastoma</Disease_Name>
      <Disease_Detail>Neuroblastoma</Disease_Detail>
      <Disease_DB>NRB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neuroblastoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Cancer, Somatic</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR078</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_cancer_somatic?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Carcinosarcoma</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_carcinosarcoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Charcot-Marie-Tooth Disease Type 1</Disease_Name>
      <Disease_Detail>Charcot-Marie-Tooth Disease</Disease_Detail>
      <Disease_DB>CHR022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/charcot_marie_tooth_disease_type_1?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glioma Somatic</Disease_Name>
      <Disease_Detail>Glioma Somatic</Disease_Detail>
      <Disease_DB>GLM037</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glioma_somatic?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Progesterone-Receptor Positive Breast Cancer</Disease_Name>
      <Disease_Detail>Progesterone-Receptor Positive Breast Cancer</Disease_Detail>
      <Disease_DB>PRG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/progesterone_receptor_positive_breast_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fallopian Tube Cancer</Disease_Name>
      <Disease_Detail>Fallopian Tube Cancer</Disease_Detail>
      <Disease_DB>FLL026</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fallopian_tube_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>in Situ Carcinoma</Disease_Name>
      <Disease_Detail>in Situ Carcinoma</Disease_Detail>
      <Disease_DB>INS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/in_situ_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Scirrhous Carcinoma</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_scirrhous_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Salivary Gland Tumor</Disease_Name>
      <Disease_Detail>Salivary Gland Tumor</Disease_Detail>
      <Disease_DB>SLV021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/salivary_gland_tumor?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pituitary Carcinoma</Disease_Name>
      <Disease_Detail>Pituitary Tumors</Disease_Detail>
      <Disease_DB>PTT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pituitary_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pleomorphic Adenoma</Disease_Name>
      <Disease_Detail>Pleomorphic Adenoma</Disease_Detail>
      <Disease_DB>PLM014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pleomorphic_adenoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glioma Susceptibility 1</Disease_Name>
      <Disease_Detail>Glioma Susceptibility</Disease_Detail>
      <Disease_DB>GLM040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glioma_susceptibility_1?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diffuse Gastric Cancer</Disease_Name>
      <Disease_Detail>Diffuse Gastric Cancer</Disease_Detail>
      <Disease_DB>DFF019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diffuse_gastric_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Papillary Serous Adenocarcinoma</Disease_Name>
      <Disease_Detail>Papillary Serous Adenocarcinoma</Disease_Detail>
      <Disease_DB>PPL007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/papillary_serous_adenocarcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hidradenoma</Disease_Name>
      <Disease_Detail>Hidradenocarcinoma</Disease_Detail>
      <Disease_DB>HDR004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hidradenoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Uterine Carcinosarcoma</Disease_Name>
      <Disease_Detail>Uterine Carcinosarcoma</Disease_Detail>
      <Disease_DB>UTR024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/uterine_carcinosarcoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastroesophageal Junction Adenocarcinoma</Disease_Name>
      <Disease_Detail>Gastroesophageal Junction Adenocarcinoma</Disease_Detail>
      <Disease_DB>GST012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastroesophageal_junction_adenocarcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Female Breast Carcinoma</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>FML027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/female_breast_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Sinonasal Undifferentiated Carcinoma</Disease_Name>
      <Disease_Detail>Sinonasal Undifferentiated Carcinoma</Disease_Detail>
      <Disease_DB>SNN002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/sinonasal_undifferentiated_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastric Cancer</Disease_Name>
      <Disease_Detail>Gastric Cancer</Disease_Detail>
      <Disease_DB>GST053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastric_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ovarian Cancer</Disease_Name>
      <Disease_Detail>Ovarian Cancer</Disease_Detail>
      <Disease_DB>OVR042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ovarian_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glassy Cell Carcinoma of the Cervix</Disease_Name>
      <Disease_Detail>Glassy Cell Carcinoma of the Cervix</Disease_Detail>
      <Disease_DB>GLS012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glassy_cell_carcinoma_of_the_cervix?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Endometrial Carcinoma</Disease_Name>
      <Disease_Detail>Endometrial Cancer</Disease_Detail>
      <Disease_DB>END042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/endometrial_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Primary Peritoneal Carcinoma</Disease_Name>
      <Disease_Detail>Primary Peritoneal Carcinoma</Disease_Detail>
      <Disease_DB>PRM126</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/primary_peritoneal_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hidradenocarcinoma</Disease_Name>
      <Disease_Detail>Hidradenocarcinoma</Disease_Detail>
      <Disease_DB>HDR006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hidradenocarcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Inflammatory Breast Carcinoma</Disease_Name>
      <Disease_Detail>Inflammatory Breast Carcinoma</Disease_Detail>
      <Disease_DB>INF023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/inflammatory_breast_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lung Cancer</Disease_Name>
      <Disease_Detail>Lung Cancer</Disease_Detail>
      <Disease_DB>LNG032</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lung_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Carcinoma in Situ</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS049</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_carcinoma_in_situ?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hereditary Diffuse Gastric Cancer</Disease_Name>
      <Disease_Detail>Hereditary Diffuse Gastric Cancer</Disease_Detail>
      <Disease_DB>HRD027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hereditary_diffuse_gastric_cancer?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenocarcinoma in Situ</Disease_Name>
      <Disease_Detail>Adenocarcinoma</Disease_Detail>
      <Disease_DB>ADN012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenocarcinoma_in_situ?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mammary Paget's Disease</Disease_Name>
      <Disease_Detail>Mammary Paget's Disease</Disease_Detail>
      <Disease_DB>MMM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mammary_pagets_disease?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipid-Rich Carcinoma</Disease_Name>
      <Disease_Detail>Lipid-Rich Carcinoma</Disease_Detail>
      <Disease_DB>LPD003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipid_rich_carcinoma?search=ERBB2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Wallerian Degeneration</Disease_Name>
      <Disease_Detail>Wallerian Degeneration</Disease_Detail>
      <Disease_DB>WLL004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/wallerian_degeneration?search=ERBB2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>HER2 Kinase Domain Complexed with TAK-285</PDB_Title>
      <PDB_ID>3RCD</PDB_ID>
      <Resolution>3.21</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RCD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold.</PubMed_Title>
      <Author>Ishikawa, T., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:8030-8050</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22003817?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HER2 extracelluar region with affinity matured 3-helix affibody ZHER2:342</PDB_Title>
      <PDB_ID>3MZW</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3MZW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for high-affinity HER2 receptor binding by an engineered protein.</PubMed_Title>
      <Author>Eigenbrot, C., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:15039-15044</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20696930?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Kinase domain of Human HER2 (erbB2).</PDB_Title>
      <PDB_ID>3PP0</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PP0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein.</PubMed_Title>
      <Author>Aertgeerts, K., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:18756-18765</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21454582?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex</PDB_Title>
      <PDB_ID>1S78</PDB_ID>
      <Resolution>3.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1S78</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.</PubMed_Title>
      <Author>Franklin, M.C., et al.</Author>
      <Journal>Cancer Cell(2004)5:317-328</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15093539?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of ErbB2 domains 1-3</PDB_Title>
      <PDB_ID>2A91</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2A91</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors</PubMed_Title>
      <Author>Garrett, T.P.J., et al.</Author>
      <Journal>Mol.Cell(2003)11:495-505</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12620236?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Water refined solution structure of the human Grb7-SH2 domain in complex with the 10 amino acid peptide pY1139</PDB_Title>
      <PDB_ID>2L4K</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2L4K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Water refined solution structure of the human Grb7-SH2 domain in complex with the erbB2 receptor peptide pY1139</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the human Grb7-SH2 domain in complex with a 10 amino acid peptide pY1139</PDB_Title>
      <PDB_ID>1MW4</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MW4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2</PubMed_Title>
      <Author>Ivancic, M., et al.</Author>
      <Journal>J.BIOMOL.NMR(2003)27:205-219</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12975581?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ErbB2 transmembrane segment dimer spatial structure</PDB_Title>
      <PDB_ID>2JWA</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2JWA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State</PubMed_Title>
      <Author>Bocharov, E.V., et al.</Author>
      <Journal>J.Biol.Chem.(2008)283:6950-6956</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18178548?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of extracellular domain of human HER2 complexed with Herceptin Fab</PDB_Title>
      <PDB_ID>1N8Z</PDB_ID>
      <Resolution>2.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1N8Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Extracellular Region of HER2 Alone and in Complex with the Herceptin Fab</PubMed_Title>
      <Author>Cho, H.-S., et al.</Author>
      <Journal>Nature(2003)421:756-760</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12610629?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Structure of ERBIN PDZ domain bound to the Carboxy-terminal tail of the ErbB2 Receptor</PDB_Title>
      <PDB_ID>1MFG</PDB_ID>
      <Resolution>1.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MFG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel mode of ligand recognition by the erbin PDZ domain</PubMed_Title>
      <Author>Birrane, G., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:1399-1402</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12444095?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Dual specific bH1 Fab in complex with the extracellular domain of HER2/ErbB-2</PDB_Title>
      <PDB_ID>3BE1</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BE1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site</PubMed_Title>
      <Author>Bostrom, J., et al.</Author>
      <Journal>Science(2009)323:1610-1614</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19299620?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Heterodimeric association of Transmembrane domains of ErbB1 and ErbB2 receptors Enabling Kinase Activation</PDB_Title>
      <PDB_ID>2KS1</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KS1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Spatial Structure of the Transmembrane Domain Heterodimer of ErbB1 and ErbB2 Receptor Tyrosine Kinases</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the single-chain Fv (scFv) fragment of an anti-ErbB2 antibody chA21 in complex with residues 1-192 of ErbB2 extracellular domain</PDB_Title>
      <PDB_ID>3H3B</PDB_ID>
      <Resolution>2.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3H3B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21.</PubMed_Title>
      <Author>Zhou, H., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:31676-31683</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21680730?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Structure of ERBIN PDZ domain bound to the Carboxy-terminal tail of the ErbB2 Receptor</PDB_Title>
      <PDB_ID>1MFL</PDB_ID>
      <Resolution>1.88</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MFL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel mode of ligand recognition by the erbin PDZ domain</PubMed_Title>
      <Author>Birrane, G., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:1399-1402</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12444095?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE</PDB_Title>
      <PDB_ID>1QR1</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QR1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide.</PubMed_Title>
      <Author>Kuhns, J.J., et al.</Author>
      <Journal>J.Biol.Chem.(1999)274:36422-36427</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10593938?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystallographic trimer of HER2 extracellular regions in complex with tryptophan-rich antibody fragment</PDB_Title>
      <PDB_ID>3N85</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N85</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine.</PubMed_Title>
      <Author>Fisher, R.D., et al.</Author>
      <Journal>J.Mol.Biol.(2010)402:217-229</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20654626?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05212</Pathway_ID>
      <Pathway_Title>Pancreatic cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05223</Pathway_ID>
      <Pathway_Title>Non-small cell lung cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05213</Pathway_ID>
      <Pathway_Title>Endometrial cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05219</Pathway_ID>
      <Pathway_Title>Bladder cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05230</Pathway_ID>
      <Pathway_Title>Central carbon metabolism in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ge.b.b.bh.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1mfg</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Dimerization</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD05590001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05590002</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05590003</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05590004</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05590005</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05590006</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05590007</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05590008</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>